Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Oncternal Therapeutics, Inc. | c16794e8vk.htm |
Exhibit
99.1
Contact:
McDavid Stilwell
GTx, Inc.
Director, Corporate Communications & Financial Analysis
901-523-9700
McDavid Stilwell
GTx, Inc.
Director, Corporate Communications & Financial Analysis
901-523-9700
GTx PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS
MEMPHIS, Tenn. — May 9, 2011 — GTx, Inc. (Nasdaq: GTXI) today provided a company update and
reported financial results for the first quarter of 2011.
“We have made strong progress in both the Ostarine and Capesaris clinical development programs,”
said Mitchell S. Steiner, MD, CEO of GTx. “The indication we will pursue for Ostarine is the
prevention and treatment of muscle wasting in patients with non-small cell lung cancer. We expect
to initiate two pivotal Phase III clinical trials in the third quarter.”
“We are also excited about our Capesaris program. We have met with the FDA and confirmed that the
primary endpoint required for approval for Capesaris for first line treatment of advanced prostate
cancer will be maintenance of castrate levels of serum total testosterone. We plan to initiate a
Phase IIb clinical trial comparing Capesaris to Lupron in advanced prostate cancer patients in the
second quarter of 2011. We expect this study to enroll quickly and to have primary efficacy results
from this open label study in the fourth quarter of this year,” Dr. Steiner said.
Clinical pipeline updates
• OstarineTM (GTx-024), a selective androgen receptor modulator, for the prevention and
treatment of muscle wasting in patients with non-small cell lung cancer: GTx has held End of Phase
II meetings with the U.S. Food and Drug Administration, or FDA, to discuss the proposed Phase III
clinical development of Ostarine (GTx-024) for the prevention and treatment of muscle wasting in
patients with non-small cell lung cancer. Based upon feedback from the FDA, GTx expects to
initiate two pivotal Phase III clinical trials for this indication in the third quarter of
2011. Muscle wasting is a common cancer related symptom that results in the decline in physical
function, reduced tolerability and response to chemotherapy, loss of independence, poor cancer
outcomes, and reduced survival.
• CapesarisTM (GTx-758), an oral selective estrogen receptor alpha agonist, for first
line treatment of advanced prostate cancer: GTx is planning to initiate in the second quarter of
2011 an open label Phase IIb clinical trial evaluating Capesaris compared to Lupron
Depot® (leuprolide acetate for depot suspension) in men with advanced prostate cancer.
GTx expects primary efficacy results of the Phase IIb clinical study, which is the proportion of
patients who become castrate by 60 days, to be available in the fourth quarter of 2011. GTx has
met with the FDA and confirmed that the primary endpoint for Phase III clinical trials required for
approval for first line treatment of advanced prostate cancer is the maintenance of castrate levels
of serum testosterone (<50 ng/dL) from Day 28 to Day 364.
• Toremifene 80 mg
for the reduction of fractures and treatment of other estrogen deficiency side
effects in men with prostate cancer on androgen deprivation therapy: GTx has evaluated the business
case for toremifene 80 mg and concluded that the Company cannot justify the expense and time
required to conduct a second Phase III clinical trial. Accordingly, GTx is discontinuing
development of toremifene 80 mg and allocating its resources to the Ostarine and Capesaris
programs.
Financial highlights for the quarter ended March 31, 2011
The net loss for the quarter ended March 31, 2011 was $2.6 million compared to a net income of
$44.3 million for the same period in 2010.
Revenue for the first quarter of 2011 was $9.3 million compared to $56.6 million for the same period
in 2010. Revenue for both periods included net sales of FARESTON® (toremifene citrate)
60 mg, marketed for the treatment of advanced metastatic breast cancer in postmenopausal women, and
collaboration revenue from Ipsen Biopharm Limited. Net sales of FARESTON were $1.2 million and
$799,000 for the three months ended March 31, 2011 and 2010, respectively. Revenue for the first
quarter of 2011 included $8.1 million of collaboration revenue as a result of
the termination of our license and collaboration agreement with Ipsen during March 2011. Revenue
for the first quarter of 2010 included collaboration revenue of $922,000 from Ipsen and the
recognition of $54.9 million of revenue due to the termination that quarter of a license and
collaboration agreement for our SARM program.
Research and development expenses for the quarter ended March 31, 2011 were $7.3 million compared
to $7.7 million for the same period in 2010. Research and development expenses for the three months
ended March 31, 2011 included a non-cash impairment charge of $1.6 million related to our
toremifene 80 mg intangible asset following the decision to discontinue development of toremifene
80 mg. General and administrative expenses for the quarter were $4.7 million compared to $4.5
million for the same period in 2010.
At March 31, 2011, GTx had cash, cash equivalents and short-term investments of $49.4 million.
Conference call
There will be a conference call today at 8:00 a.m. Eastern Time. To listen to the conference call,
please dial 866-831-6247 from the United States or Canada or 617-213-8856 from other international
locations. The access code for the call is 97712705. A playback of the call will be available from
approximately 12:00 p.m. Eastern Time today through May 23, 2011 and may be accessed by dialing
888-286-8010 from the United States or Canada or 617-801-6888 from other international locations
and referencing reservation number 42500165. Additionally, you may access the live and subsequently
archived webcast of the conference call from the Investor Relations section of the Company’s
website at http://www.gtxinc.com.
About GTx
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of small molecules that selectively target hormone
pathways for the treatment of cancer, cancer supportive care, and other serious medical conditions.
Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements based upon GTx’s current expectations.
Forward-looking statements include, but are not limited to, statements relating to GTx’s plans to
initiate clinical trials for OstarineTM (GTx-024) and Capesaris™ (GTx-758) and
statements related to the therapeutic potential of GTx’s product candidates. Forward-looking
statements
involve risks and uncertainties. GTx’s actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risks (i) that GTx will not be able to
commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in
humans; (ii) that GTx may not be able to obtain required regulatory approvals to commercialize its
product candidates in a timely manner or at all; (iii) that clinical trials planned to be conducted
by GTx may not be initiated or completed on schedule, or at all, or may otherwise be suspended or
terminated; (iv) that GTx could utilize its available cash resources sooner than it currently
expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or
eliminate its product candidate development programs or commercialization efforts. You should not
place undue reliance on these forward-looking statements, which apply only as of the date of this
press release. GTx’s annual report on Form 10-K, filed with the Securities and Exchange Commission
on March 8, 2011, contains under the heading, “Risk Factors”, a more comprehensive description of
these and other risks to which GTx is subject. GTx expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.
GTx, Inc.
Condensed Balance Sheets
(in thousands)
Condensed Balance Sheets
(in thousands)
| March 31, | December 31, | |||||||
| 2011 | 2010 | |||||||
| (unaudited) | ||||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 42,790 | $ | 58,181 | ||||
Short-term investments |
6,575 | 450 | ||||||
Accounts receivable, net |
680 | 683 | ||||||
Inventory |
164 | 171 | ||||||
Prepaid expenses and other current assets |
1,666 | 875 | ||||||
Total current assets |
51,875 | 60,360 | ||||||
Property and equipment, net |
1,764 | 2,040 | ||||||
Intangible and other assets, net |
223 | 1,850 | ||||||
Total assets |
$ | 53,862 | $ | 64,250 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 658 | $ | 848 | ||||
Accrued expenses and other current liabilities |
2,576 | 3,112 | ||||||
Deferred revenue — current portion |
— | 1,345 | ||||||
Total current liabilities |
3,234 | 5,305 | ||||||
Deferred revenue, less current portion |
— | 6,721 | ||||||
Other long-term liabilities |
246 | 497 | ||||||
Commitments and contingencies |
||||||||
Stockholders’ equity: |
||||||||
Common stock, $0.001 par value: 60,000,000
shares authorized; 51,719,187 shares issued
and outstanding at March 31, 2011 and
December 31, 2010 |
52 | 52 | ||||||
Additional paid-in capital |
405,805 | 404,555 | ||||||
Accumulated deficit |
(355,475 | ) | (352,880 | ) | ||||
Total stockholders’ equity |
50,382 | 51,727 | ||||||
Total liabilities and stockholders’ equity |
$ | 53,862 | $ | 64,250 | ||||
GTx, Inc.
Condensed Statements of Operations
(in thousands, except share and per share data)
(unaudited)
Condensed Statements of Operations
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2011 | 2010 | |||||||
Revenues: |
||||||||
Product sales, net |
$ | 1,229 | $ | 799 | ||||
Collaboration revenue |
8,066 | 55,778 | ||||||
Total revenues |
9,295 | 56,577 | ||||||
Costs and expenses: |
||||||||
Cost of product sales |
205 | 151 | ||||||
Research and development expenses |
7,303 | 7,650 | ||||||
General and administrative expenses |
4,684 | 4,509 | ||||||
Total costs and expenses |
12,192 | 12,310 | ||||||
(Loss) income from operations |
(2,897 | ) | 44,267 | |||||
Other income, net |
302 | 72 | ||||||
Net (loss) income |
$ | (2,595 | ) | $ | 44,339 | |||
Net (loss) income per share: |
||||||||
Basic and diluted |
$ | (0.05 | ) | $ | 1.22 | |||
Weighted average shares used in computing net (loss) income per share: |
||||||||
Basic and diluted |
51,719,187 | 36,420,901 | ||||||